Oxford University Press | Online Resource Centre

Choose your answers from a-d by clicking the radio button next to each choice and then press 'Submit' to get your score.

Question 01

Risk factors associated with colorectal cancer include which one of the following?

a) Irritable bowel syndrome

b) Low intake of dietary fibre

c) Low intake of red meat

d) Chronic aspirin therapy

Question 02

Colorectal cancer:

a) is more common in males.

b) is the most common cancer in the UK.

c) most commonly occurs in the caecum.

d) commonly arises from pre-existing adenomas.

Question 03

Characteristic presenting features of left sided colorectal tumours include:

a) acute large bowel obstruction.

b) iron deficiency anaemia.

c) painless abdominal mass.

d) foul smelling stools which are difficult to flush.

Question 04

Features associated with poor prognosis in colorectal cancer include:

a) adenocarcinoma cell type.

b) rectal bleeding at presentation.

c) presence of involved lymph nodes.

d) lymphocytic response to tumour.

Question 05

Surgery for liver metastases from colorectal cancer is:

a) associated with a 10% mortality.

b) contraindicated if more than 1 lesion is present.

c) associated with 16-40% 5 year survival.

d) usually followed with consolidation radiotherapy.

Question 06

5 Fluorouracil based chemotherapy:

a) is indicated for all patients with Duke's B tumours.

b) in combination with capecitabine improves survival to around 18 months in metastatic disease.

c) is likely to impair quality of life when used in the metastatic setting.

d) improves 5 year survival rates for patients with Duke's C tumours by approximately 7%.

Question 07

Which of the following is a feature of colorectal cancer?

a) In Duke's A disease >90% patients are cured by surgery alone.

b) Distant metastases are present in less than 5% of patients at presentation.

c) Chemotherapy has no effect on survival.

d) In Duke's C disease <30% patients will relapse within 5 years.

Question 08

Bevacizumab:

a) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF).

b) is a monoclonal antibody that targets epidermal growth factor receptor (EGFR).

c) has no proven survival benefit in the metastatic setting.

d) is standard treatment for metastatic colorectal cancer in the UK.

Question 09

Regarding metastases from colorectal cancer and symptomatic management of them:

a) liver metastases are a rare feature.

b) hyperproteinaemia is common.

c) liver capsular pain usually responds well to non-steroidal anti-inflammatory drugs.

d) cerebral metastases are common.

Question 10

Acute bowel obstruction in advanced colorectal cancer:

a) is usually managed by surgery.

b) is usually caused by obstruction at a single site in the bowel.

c) should be treated with regular oral anti-emetics, analgesics and anti-spasmodics.

d) should be treated with using a syringe driver containing a mixture of anti-emetics, analgesics and anti-spasmodics.

Oxford University Press, Online Resource Centre, Colorectal Cancer.

Colorectal Cancer

Instructions